INTRODUCTION
The gut lumen hosts 90% of the microorganisms in the human body. This microbiota community benefits the host by extracting energy and nutrients from food, by preventing colonization of pathogenic species (Hooper and Gordon, 2001) , and by regulating immune cell function (Maloy and Powrie, 2011) . The epithelial intestinal barrier is an essential boundary that precludes bacterial entry and maintains mucosal homeostasis. Deregulation of intestinal homeostasis, with concomitant aberrant activation of mucosal innate and adaptive immunity, can result in gut injury, inflammation, and inflammatory bowel disease (IBD). However, the fundamental pathophysiologic mechanisms underlying IBD are still unclear.
The interaction between the B7 family members and their receptors provides critical costimulation and coinhibition, which regulate T cell function. In addition to the long-established pathway of B7-1/B7-2-CD28/CTLA-4, the interaction between B7-H1 (PD-L1) (Dong et al., 1999; Freeman et al., 2000) , a member of the B7 family, and its receptor PD-1, a member of the CD28 family, has a major role in inhibiting T cell responses (Freeman et al., 2000) and in inducing CD8 T cell exhaustion during viral infections (Day et al., 2006) . Given that B7-H1 is mainly expressed on immune cells and PD-1 is expressed on activated T cells, research on this pathway has primarily focused on T cell coinhibition; nonetheless, the role of the B7-H1/PD-1 pathway in T cell-mediated intestinal inflammation and IBD remains largely unknown. A few earlier works report that the administration of anti-B7-H1 suppresses intestinal inflammation (Kanai et al., 2003) , whereas the loss of PD-1/ PD-L1 signaling leads to expansion of gut antigen-specific CD8 T cells (Reynoso et al., 2009) , and the PD-1 blockade in simian-immunodeficiency-virus-infected monkeys enhances repair of gut-associated junctions (Dyavar Shetty et al., 2012) . B7-H1 can also be detected on some tissue cells (Liang et al., 2003) , but its function is largely unexplored. Here, we identified epithelium-expressed B7-H1 as a key regulator of intestinal inflammation and colitis by inhibiting innate immune cells.
RESULTS

B7-H1 Protects from Mortality and Morbidity in Two Models of Intestinal Injury
To investigate B7-H1 function in gut immunity, we chose a chemical model of intestinal injury utilizing oral administration of dextran sodium sulfate (DSS) that injures the colonic epithelium (Okayasu et al., 1990) and triggers potent inflammatory responses (Rakoff-Nahoum et al., 2004). B7-H1-deficient (B7-H1 À/À ) mice showed much higher mortality and morbidity (weight loss, anal bleeding, diarrhea, and anal erosion scores) upon DSS administration (2%; w/v) for 6 days ( Figure 1A ) than wild-type (WT) mice. Although less than 20% of B7-H1 À/À mice survived, more than 70% of WT mice remained alive. Higher DSS concentration (4%) for a shorter time (5 days) provided similar results with an earlier onset of disease (data not shown).
We extended studies to a 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis model and obtained similar results (Figure S1A) . Thus, B7-H1 is critical for controlling intestinal epithelial injury and inflammation.
We dissected the causes of death and morbidity in B7-H1
mice by histopathological analyses of colon tissues. Although colonic bleeding in B7-H1 À/À mice occurred earlier than in WT mice ( Figure 1A ), both groups of mice became anemic at day 6 of DSS treatment (data not shown). Hematoxylin and eosin (H&E) analyses confirmed that B7-H1 À/À mice displayed more severe ulceration, extensive epithelium erosion, and cellular infiltration ( Figures 1B and 1C ). In addition, we found an enlargement of distinct lymphoid aggregations known as ''mucosal associated lymphoid tissues'' (MALTs) beneath the epithelium in B7-H1 À/À mice ( Figures 1B and 1D ), which correlates with severe (A) Wild-type (WT) and B7-H1 À/À mice were fed with 2% DSS in drinking water for 7 days. Survival, percentage of original weight loss, anal bleeding, diarrhea, anal erosion, and colonic blood scores were monitored. Survival data are represented as Kaplan-Meier curves, ***p < 0.001; log rank test. Data were pooled from two independent experiments (n = 15/group). *p < 0.05; **p < 0.01; ***p < 0.001; Student's t test.
(B) H&E-stained colon tissue of DSS-treated WT and B7-H1 À/À mice (D0, D2, and D6).
(C and D) Histopathological scoring of infiltrating leukocytes, edema, ulcerationl, and MALT area (n = 20 MALTs/mouse) in WT and B7-H1 À/À mice (D6; scale bars represent 100 mm; arrows indicate MALTs). ***p < 0.001; Student's t test.
(E) DSS-fed mice were gavaged (D0 and D6) with FITC-dextran. Three hours later, FITC fluorescence was determined in sera. Data are pooled from two independent experiments (n = 6-9). *p < 0.05; Student's t test.
(F) CFUs in feces and colon of DSS-fed mice (D0, D2, and D6); *p < 0.05; Mann-Whitney U test. (G) Quantitative PCR analysis of 16S rDNA copies for the whole bacterial kingdom in the feces of DSS-treated (D0 and D6) WT and B7-H1 À/À mice.
Data were pooled from two independent experiments, n = 3-4. *p < 0.05; Student's t test.
pathological changes (Laukoetter et al., 2007) . Neither naive B7-H1 À/À nor naive WT mice showed signs of colonic inflammation or tissue damage. Augmented mucosal permeability and intestinal barrier dysfunction are associated with colitis development in mice (Garrett et al., 2007) and IBD patients (Cobrin and Abreu, 2005) . Therefore, we investigated the role of B7-H1 in maintaining gut epithelial integrity by orally gavaging mice with fluorescein isothiocyanate (FITC)-dextran (Garrett et al., 2007) . We found a 4-fold increase of FITC-dextran levels in sera of B7-H1 À/À mice at day 6 of DSS treatment ( Figure 1E ), suggesting that B7-H1 is important for regulation of intestinal permeability during gut injury.
Intestinal microbial populations vary enormously between IBD patients and healthy individuals (Hooper and Gordon, 2001 ); therefore, we analyzed their concentration and composition. After DSS administration, B7-H1 À/À mice had higher bacteria colony-forming units (CFUs) not only in feces and colon (Figure 1F) , but also in mesenteric lymph nodes (MLNs), spleen, and liver (data not shown) than WT mice, suggesting the presence of a bacterial systemic dissemination in B7-H1 À/À mice.
Quantitative analysis of 16S rDNA confirmed that B7-H1
mice had an increased number of total bacteria than WT mice ( Figure 1G ), but none of the specific intestinal microbiota groups analyzed accounted for this increase ( Figure S1B ). Altogether, our findings demonstrate that B7-H1 is required to maintain gastrointestinal integrity during gut inflammation and to avoid commensal bacteria overgrowth.
B7-H1 Expression on Intestinal Parenchyma Confers
Protection B7-H1 is constitutively expressed on a wide range of immune and tissue cells and is upregulated after activation (Freeman et al., 2000; Liang et al., 2003) . As the colon is the site of DSSinduced disease, we examined B7-H1 expression in the colon. (Mifflin et al., 2011) . We found B7-H1 was expressed on both colonic parenchymal and hematopoietic cells from naive and DSS-treated WT mice, and it was moderately upregulated on cytokeratin À CD45 + cells at D6 of DSS treatment ( Figure 2A ). B7-H1 expression was also increased on colon of IBD patients ( Figure 2B ). PD-1, the receptor for B7-H1, is not expressed on parenchymal cells but is mainly expressed on activated T and B cells (Agata et al., 1996) , on exhausted CD8 T cells (Barber et al., 2006; Day et al., 2006) and on dendritic cells (DCs) (Yao et al., 2009) or monocytes or macrophages (Huang et al., 2009 ) during infection. We detected PD-1 on colonic hematopoietic cells of both WT and B7-H1 À/À mice before and after DSS administration, respectively ( Figure 2A ). We next asked whether B7-H1 on hematopoietic cells and/or parenchymal cells was required to inhibit the pathogenic process during DSS-induced disease. We generated B7-H1 bone marrow (BM) chimera mice with control groups ( Figure S2A ). Upon DSS administration, B7-H1 À/À mice reconstituted with WT BM developed significantly worse clinical symptoms as compared to WT mice reconstituted with B7-H1 À/À BM or with WT BM ( Figure 2C ). Only 10% of mice survived in the first group versus 70%-80% in the other two groups. The first group also showed severe histopathological changes in colon tissue sections stained with H&E ( Figure 2D ). These findings, together with the B7-H1 expression pattern on colonic cell populations, suggest that B7-H1 on parenchyma, but not on hematopoietic cells, confers protection from intestinal injury and inflammation.
Effect of B7-H1 on Intestinal Epithelium Homeostasis
To understand how intestinal epithelium-expressed B7-H1 regulates intestinal injury and inflammation, we considered two possible mechanisms: cell-intrinsic alterations and cell-extrinsic interactions. A possible cell-intrinsic mechanism could be a homeostatic imbalance of intestinal epithelium in the absence of B7-H1. We hypothesized that intestinal epithelium-expressed B7-H1 controls intestinal injury by affecting proliferation or by impairing apoptosis of intestinal epithelial cells. To assess the proliferation, we used an immunofluorescence staining for Ki67 and the 5-bromo-2 0 -deoxyuridine (BrdU) assay. Our data showed a slightly higher baseline level (D0) of proliferation in B7-H1 À/À mice ( Figure S2B ), which quickly disappeared at D2 and did not correlate with an alteration of the intestinal epithelial permeability ( Figure 1E ) or with colonic hyperplasia (data not shown). However, upon inflammation (D6), both B7-H1 À/À and WT colonic cells exhibited a similar epithelial proliferative capacity ( Figure S2B ). Another possible cell-intrinsic mechanism accounting for the dysregulation of intestinal epithelial cells in B7-H1 À/À mice is increased cell death. Analyses of apoptosis and necrosis in colon epithelial cells showed an increased number of both apoptotic and necrotic epithelial cells in B7-H1 À/À mice at D6
of DSS-treatment (Figures 3A and 3B) . Altogether, these results demonstrated that B7-H1 did not affect tissue repair processes after an injurious insult, but it prevents apoptosis and necrosis of intestinal epithelial cells during gut inflammation.
Protective Function of B7-H1 Is Not Dependent on Adaptive Immunity
We next explored a cell-extrinsic mechanism by testing the hypothesis that intestinal parenchymal cells expressed B7-H1 could interact with immune cells and, as a consequence, reduce intestinal inflammation. Both innate and adaptive immunity contribute to intestinal inflammation (Maloy and Powrie, 2011) . Therefore, we analyzed immune cell populations in the colon and MLN and found no difference in the number of T and B cells, NK/NKT cells, macrophages, DCs, neutrophils, myeloid, and innate lymphoid cells ( Figure S3A ). To assess if components of the adaptive immune system including T and B cells could participate in the B7-H1-mediated protection, we generated Rag-1
B7-H1
À/À mice and found that these mice exhibited significant higher mortality and morbidity than Rag-1 À/À mice after DSS administration ( Figure 3C ). Compared to WT mice reconstituted with WT BM, WT mice reconstituted with PD-1 À/À BM seemed to be slightly more sensitive to DSS-induced colitis without reaching significant difference ( Figure 3D ), which correlates with no significant difference between PD-1 À/À mice and WT mice during DSS treatment ( Figure 3E ). However, we cannot exclude the involvement of PD-1 on radioresistant PD-1 positive tissue resident innate cells. These unexpected findings demonstrated that B7-H1 delivered protection from intestinal injury and inflammation in the absence of adaptive immunity.
B7-H1 Inhibits Tumor Necrosis Factor a Production and Enhances Interleukin 22 Production from CD11c
+ CD11b + LP Inflamed Cells Tumor necrosis factor a (TNF-a) has been shown to have a major role in the pathogenesis of IBD (Dharmani et al., 2011) . Thus, we measured cytokines in the colon and found B7-H1 À/À colons produced about 3-fold more TNF-a than WT colons at D6 of DSS treatment ( Figure 4A ), whereas the levels of cytokines interleukin 6 (IL-6), IL-2p70, IL-4, IFN-g, and MCP-1 were comparable ( Figure S3B ). Next, we evaluated innate immune cell activity in the colon. Intracellular cytokine staining of inflamed LP cells (D6) revealed that CD11c + CD11b + cells in B7-H1 À/À mice significantly enhanced TNF-a production ( Figure S4A ) despite a similar expression of surface activation markers in both groups of mice (data not shown). Treatment with anti-TNF-a neutralizing antibody reduced by 50% the mortality in B7-H1 À/À mice as compared to isotype-treated mice ( Figure 4B ). These data indicate that TNF-a is one of the major causes of mortality in were treated with 3% DSS in drinking water for 6 days. Survival, percentage of original weight loss, anal bleeding, diarrhea, and anal erosion score were monitored. Data represent one of three independent experiments, n = 7-10. Survival data are represented as Kaplan-Meier curve (*p < 0.05; log rank test). *p < 0.05; **p < 0.01; Student's t test. (D) H&E staining of colon tissue sections of chimera colons (D0 and D6). Scale bars represent 100 and 50 mm.
B7-H1
À/À mice, suggesting a cell-extrinsic mechanism where B7-H1 might inhibit TNF-a production from CD11c + CD11b + LP cells. To test this possibility, we generated a B7-H1-Ig fusion protein and found that plate-bound B7-H1-Ig protein, but not control Ig protein, suppressed TNF-a production from both WT and PD-1 Figure 4C ) as B7-1 has been found as an additional binding molecule (Butte et al., 2007) . These data indicate the PD-1/B7-H1 pathway alone or the B7-1/B7-H1 pathway alone may not significantly contribute to the disease onset in B7-H1 À/À mice.
IL-22 induces innate immune response during mucosal infections (Aujla et al., 2008) and promotes colonic epithelial cell restitution including induction of antimicrobial peptides such as Reg3-g and b-defensins (Wolk et al., 2004) . We investigated whether the cell-extrinsic mechanism so far observed could promote a release of protective factors like IL-22 and TGF-b. We found WT colon supernatants had higher levels of IL-22 than B7-H1 À/À samples, but no difference for TGF-b was detected ( Figure 4A ). Interestingly, we discovered IL-22 production was strongly produced by WT À/À mice were fed with 3% DSS in drinking water for 6 days and monitored for survival, body weight loss, anal bleeding, and diarrhea score.
Data are representative of four independent experiments, n = 9. Survival data are showed as Kaplan-Meier curves (*p < 0.05; log rank test). Data represent means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; Student's t test.
CD11b
+ CD103 + dendritic cells, which have a tolerogenic phenotype (Maloy and Powrie, 2011) , but not from CD11b + CD103 À DCs ( Figure 4D ). Finally, we found, in a coculture assay, WT primary intestinal epithelial cells (IECs) were able to stimulate IL-22 production from WT CD11c + CD11b + LP cells significantly better than B7-H1 À/À IECs ( Figure 4E ).
These data proved B7-H1 is required on the intestinal epithelium to dampen the inflammation by CD11c demonstrate that tissue-expressed B7-H1 is an essential regulator in the control of intestinal inflammation.
DISCUSSION
Beside the classical coinhibitory function of the B7-H1/PD-1 pathway in T cell activation and immune pathology (Keir et al., 2008) , very few data are available on the role of tissue-expressed (B) WT and B7-H1 À/À mice were intraperitoneally injected with anti-TNF-a blocking antibody or isotype control or PBS starting at D0 of 3% DSS treatment and every other day until D20. Survival, percentage of original weight loss, anal bleeding, diarrhea, and anal erosion were monitored. Data were pooled from two independent experiments (n = 8/group). Survival data are represented as Kaplan-Meier curves. **p < 0.01; ***p < 0.001; log rank test; *p < 0.05; **p < 0. We revealed two unexpected functions for B7-H1. First, B7-H1-mediated protection during intestinal inflammation minimally required the expression of PD-1 on hematopoietic cells because the morbidity and mortality observed in PD1 À/À chimera mice were slightly increased but were not statistically different from that of control chimera mice. Second, B7-H1 expressed on tissue cells, but not on hematopoietic cells, was essential for reducing gut pathogenesis because chimera mice lacking B7-H1 expression on parenchyma exhibited an increased mortality and morbidity during DSS-induced colitis, whereas chimera mice lacking B7-H1 expression on hematopoietic cells showed minimal signs of disease. These results, together with other reports in type 1 diabetes (Keir et al., 2006) and LCMV infection (Mueller et al., 2010) , highlight an emerging role for tissueexpressed B7-H1 in the control of peripheral immune responses.
In addition, we found that adaptive immune response was not required for B7-H1 protection, because Rag-1
B7-H1
À/À mice developed more severe gut pathogenesis than control Rag-1 À/À mice. These data suggest that B7-H1 controls intestinal inflammation through innate immunity, which is in line with previous reports on the role of innate immunity in DSS-induced colitis (Garrett et al., 2007; Rakoff-Nahoum et al., 2004; Zaki et al., 2010) . TNF-a has been recognized as a master cytokine in the onset of DSS-induced colitis (Dharmani et al., 2011) , and anti-TNF-a therapy inhibits IEC apoptosis in patients with IBD (Marini et al., 2003) . The increased TNF-a production observed in inflamed B7-H1 À/À colons corresponded with the peak of mortality and intestinal epithelial apoptosis, and the disease was successfully ameliorated by TNF-a blockade, indicating that B7-H1 is one of the major inhibitors of the TNF-a production in this disease model. An in vitro evidence of the B7-H1 inhibitory effect was provided using B7-H1-Ig fusion protein, which impaired the TNF-a production of inflamed CD11c + CD11b + LP cells isolated from WT or PD-1 À/À B7-1 À/À mice. These data showed not only that B7-H1 inhibited innate cells, but also that the B7-H1/PD-1 pathway alone or the B7-H1/B7-1 pathway alone might not be primarily involved. In addition to PD-1 and B7-1, new studies also demonstrate unidentified receptor(s) for B7-H1 (Xu et al., 2013) . Given that the multiple interactions of those molecules could raise some difficulties for the data interpretation of these different pathways, further investigations on the specific functions of those molecules are warranted to better understand their specific roles in the maintenance of intestinal peripheral tolerance. Different subsets of intestinal dendritic cells are known to play crucial roles in the maintenance of intestinal tolerance by inducing tolerogenic T cell responses including increasing TGF-b and retinoic acid levels (Maloy and Powrie, 2011) . Our data showed that, although TGF-b was not differentially regulated, IL-22 levels were significantly increased in mice expressing B7-H1. We further proved that IL-22 production was strongly impaired when B7-H1 À/À IECs were cultured with DSS-inflamed LP. These data revealed a role for B7-H1 expressed on IECs by regulating IL-22 production for the epithelial restoration process.
Thus, a lack of B7-H1 could skew the mucosal intestinal responses toward a proinflammatory phenotype leading to increased inflammation and injury. Strategies that specifically enhance the activation of B7-H1 in the parenchyma would be beneficial for therapeutic control of IBD.
EXPERIMENTAL PROCEDURES Mice
B7-H1
À/À and PD-1 À/À mice were previously described (Dong et al., 2004 ).
C57BL/6, Rag1 À/À on C57BL/6 background, and B7-1 À/À on C57BL/6 background mice were purchased from the Jackson Laboratory and bred at the Albert Einstein Animal Facility. Rag1
were obtained by intercrossing Rag1 À/À with B7-H1 À/À and PD-1 À/À with B7-1 À/À mice, respectively. Mice were housed in the same room in a specific pathogen-free facility and used for studies at 7-9 weeks old under protocols approved by the Institutional Animal Care and Use Committee.
Experimental Colitis Models DSS-mediated colitis was induced by oral administration of 2%, 3%, and 4% (w/v) of DSS (molecular weight 36,000-50,000, MP Biomedicals) in drinking water for 7, 6, and 5 days, respectively, ad libitum; then, water was replaced until day 20. TNBS-mediated colitis was induced by intrarectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS) at 15 mg/kg body weight diluted in 50% ethanol at day 0. The intensity of colitis for both models was monitored daily and clinical parameters were determined as follows: anal erosion (score 0-3; 0 = normal; 1 = mild; 2 = moderate; 3 = severe), anal bleeding (score 0-3: 0 = normal; 1 = mild; 2 = moderate; 3 = severe), diarrhea (score 0-3; 0 = normal; 1 = mild; 2 = moderate; 3 = severe), and percentage of body weight loss.
Statistical Analysis
Data were expressed as mean ± SEM. Student's t test or Mann-Whitney test were performed, and p values < 0.05 using a 95% confidence interval were considered significant. Survival graphs were represented as Kaplan-Meier curves and analyzed with log rank test. The GraphPad Prism statistical software program (GraphPad Software) was used for all analyses. Other detailed experimental procedures can be found in the Supplemental Experimental Procedures. Figure S1 . Mortality and morbidity of B7-H1-/-mice upon TNBS treatment and microbiota groups after DSS treatement (A) TNBS treatment in WT and B7-H1-/-mice. Wild-type (n=18) and B7-H1-/-mice (n=17) were intrarectally instilled with TNBS at day 0. Survival and bleeding score were monitored after TNBS administration. Data were pooled from two independent experiments. Survival data are represented as Kaplan-Meier curves (** P < 0.01; *** P < 0.001; log-rank test). Data represent means ± S.E.M. (* P < 0.05, ** P < 0.01, *** P < 0.001; Student's t test). Immunoperoxidase method was used for detection. For immunofluorescence staining we used an anti-FITC-Pan Cytokeratin and an anti-Ki67 antibodies followed by a secondary antibody. DAPI (Invitrogen) was used to detect nucleus.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
At least 10 fields/mouse were blindly analyzed with an Olympus BX61.
Blockade of TNF-α
100 µg of monoclonal anti-mouse TNF-α blocking antibody (BioXCell, BE0058) or an isotype-matched control rat IgG1 (BioXCell, BE0088) were injected i.p into mice every other day for up to 20 days of DSS treatment starting at day 0. 
Analysis of red blood cells
Flow cytometry reagents
Single-cell suspensions isolated from colons were washed in FACS buffer (icecold 0.5% BSA in PBS) and stained with specific antibodies from eBioscience:
FITC-CD62L (MEL-14), APC-CD45R (RA3-6B2), PE-CD11b (M1/70), APC-F4/80
